Author | Caron A. Jacobson, MD

Articles

Caron A. Jacobson, MD, on Next Steps for the Phase 2 ZUMA-5 Study

August 02, 2020

Interim results from the study suggested that axicabtagene ciloleucel (axi-cel) demonstrated significant and durable clinical benefit in patients with relapsed or refractory indolent non-Hodgkin lymphoma.

Caron A. Jacobson, MD, on What Patients Should Know About the Phase 2 ZUMA-5 Study

July 14, 2020

ByCaron A. Jacobson, MD

The expert in hematology discussed what patients should know about the study, which evaluated the use of axicabtagene ciloleucel (axi-cel) in patients with relapsed or refractory indolent non-Hodgkin lymphoma.

Phase 2 ZUMA-5 Study Results Show Promise for Axi-Cel in Indolent Non-Hodgkin Lymphoma

June 27, 2020

ByCaron A. Jacobson, MD

Results from the phase 2 ZUMA-5 study indicated that axicabtagene ciloleucel (axi-cel) may be a promising approach for treating this patient population.

Caron A. Jacobson, MD, on the Findings of the Phase 2 ZUMA-5 Study

June 14, 2020

ByCaron A. Jacobson, MD

The study assessed the use of axicabtagene ciloleucel in patients with relapsed or refractory indolent non-Hodgkin lymphoma.